Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (311-320 of 355) with videos related to

Pageof 36
Sort By:
The Pediatric Infectious Disease Journal|September 27, 2012
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccinesDong Soo Kim, Seon Hee Shin, Hoan Jong Lee, et al.
The New England Journal of Medicine|February 3, 2023
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent VaccineJing Zou, Chaitanya Kurhade, Sohil Patel, et al.
The New England Journal of Medicine|April 27, 2022
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in PregnancyEric A F Simões, Kimberly J Center, Alan T N Tita, et al.
Pediatrics|March 18, 2015
13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infantsFederico Martinón-Torres, Hanna Czajka, Kimberly J Center, et al.
The Lancet. Infectious Diseases|June 16, 2025
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trialBabalwa Jongihlati, Nathan Segall, Stanley L Block, et al.
Vaccine|March 7, 2017
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinationsJacek Wysocki, Kimberly J Center, Jerzy Brzostek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2015
Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine eraSheldon L Kaplan, Kimberly J Center, William J Barson, et al.
Journal of Medicinal Chemistry|September 1, 2000
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitorsA Wissner, D M Berger, D H Boschelli, et al.
The Journal of Infectious Diseases|January 21, 2006
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humansPeter F Wright, Ruth A Karron, Shabir A Madhi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memoryAndrés de Roux, B Schmöle-Thoma, B Schmöele-Thoma, et al.
Pageof 36

Showing results (311-320 of 355) with videos related to

Sort By:
Pageof 36
The Pediatric Infectious Disease Journal|September 27, 2012
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccinesDong Soo Kim, Seon Hee Shin, Hoan Jong Lee, et al.
The New England Journal of Medicine|February 3, 2023
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent VaccineJing Zou, Chaitanya Kurhade, Sohil Patel, et al.
The New England Journal of Medicine|April 27, 2022
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in PregnancyEric A F Simões, Kimberly J Center, Alan T N Tita, et al.
Pediatrics|March 18, 2015
13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infantsFederico Martinón-Torres, Hanna Czajka, Kimberly J Center, et al.
The Lancet. Infectious Diseases|June 16, 2025
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trialBabalwa Jongihlati, Nathan Segall, Stanley L Block, et al.
Vaccine|March 7, 2017
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinationsJacek Wysocki, Kimberly J Center, Jerzy Brzostek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2015
Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine eraSheldon L Kaplan, Kimberly J Center, William J Barson, et al.
Journal of Medicinal Chemistry|September 1, 2000
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitorsA Wissner, D M Berger, D H Boschelli, et al.
The Journal of Infectious Diseases|January 21, 2006
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humansPeter F Wright, Ruth A Karron, Shabir A Madhi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memoryAndrés de Roux, B Schmöle-Thoma, B Schmöele-Thoma, et al.
Pageof 36